FIELD: medicine, rheumatology. SUBSTANCE: method involves the combined therapy with methotrexat and prospidinum prescribed by intravenous route of administration: methotrexat in the dose 10 mg per a week and prospidinum in the dose 200-300 mg per a week. Method provides the early and expressed effect of treatment and reducing complications in carrying out the immunosuppressive therapy. Invention can be used in treatment of patients with psoriatic arthritis. EFFECT: improved treatment method. 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF ANKYLOSING SPONDYLARTHRITIS | 2003 |
|
RU2231356C1 |
| METHOD FOR TREATING RHEUMATOID ARTHRITIS | 2001 |
|
RU2199320C1 |
| METHOD FOR DETERMINING INDICATIONS TO BEGINNING OF RECEPTION OF GENETIC ENGINEERING BIOLOGICAL PREPARATIONS WITH INEFFECTIVENESS OF BASIC ANTI-INFLAMMATORY PREPARATIONS IN EARLY FORMS OF PSORIATIC ARTHRITIS | 2020 |
|
RU2731807C1 |
| METHOD FOR ASSESSING RISK OF SACROILIITIS PROGRESSION IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS | 2024 |
|
RU2837143C1 |
| METHOD FOR PREVENTING OSSEOUS-CARTILAGINOUS DESTRUCTION IN CASE OF RHEUMATOID ARTHRITIS | 2003 |
|
RU2268719C2 |
| METHOD FOR TREATING CHRONIC GONARTHRITIS IN PATIENTS WITH OSTEOARTHROSIS | 2005 |
|
RU2293560C2 |
| METHOD FOR ASSESSING THE RISK OF JOINT EROSIONS IN PATIENTS WITH PSORIATIC ARTHRITIS | 2022 |
|
RU2791661C1 |
| METHOD OF TREATING PSORIATIC ARTHROPATHY PATIENTS | 0 |
|
SU1602522A1 |
| METHOD FOR ASSESSING POSSIBILITY OF ACHIEVING MINIMUM DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS | 2024 |
|
RU2829416C1 |
| METHOD FOR PREDICTING THE COURSE OF PSORIATIC ARTHRITIS | 2021 |
|
RU2765111C1 |
